However, only a few clinical trials (CXCL10; MDX-10 (14), CX3CL1; E6011 and CCR1; CCX354-C (55)) of 10 drugs that target the chemokine system had some clinical benefits in RA patients (Table 3). Here, CCR1 is linked to rheumatoid arthritis.